The blockbuster weight-loss drugs that many households could not afford are getting markedly cheaper under a pricing arrangement between the federal government and the two companies that make them. Starting-dose versions of drugs like Wegovy, Zepbound, and the Ozempic class are being sold for about $350 a month in cash, and Medicare enrollees are looking at roughly $245 with a $50 monthly copay. The shift is notable not just for the sticker price but because Medicare is now covering obesity treatment at all.
The most-favored-nation deal with Lilly and Novo Nordisk
The price cuts trace to a most-favored-nation pricing deal the Trump administration struck with Eli Lilly and Novo Nordisk, the two drugmakers behind the best-known GLP-1 medications, announced in November 2025 and rolling out through 2026. The idea behind that framework is to tie U.S. prices for these medications closer to what other wealthy countries pay, which historically has been far less than American patients face at the pharmacy counter. Because the change is phasing in on a timeline rather than switching on all at once, the exact price a patient sees can depend on when and how they buy.
The deal is unusual in reaching directly to consumers rather than only to insurers, which is why a cash price is part of the story at all. Both manufacturers agreed to sell through a government-linked channel and to let prices drift lower over time. An overview of the announcement and what the companies agreed to is available from AJMC.
Free retirement updates: One number can cost or save hundreds a month in retirement. The free Retirement Shield newsletter surfaces the ones worth knowing. Sign up free.
About $350 cash through TrumpRx
For people paying out of pocket, the drugs are being offered at about $350 a month for the starting dose through a direct-to-consumer platform called TrumpRx, which launched in January 2026. That cash price is set to trend downward toward $245 over the next two years under the terms of the deal. The $350 figure applies to the starting dose, and buyers still need a valid prescription, so it is not a flat price for every dose or every patient. For a household that had priced these medications well out of reach, a few hundred dollars a month is still a real expense, but it is a different order of magnitude from the list prices that kept many people from starting treatment at all. The medications covered by the arrangement include Wegovy, Zepbound, and the Ozempic class, spanning both major manufacturers. Details of how the pricing is structured across the drugs are covered in an analysis from the Academy of Managed Care Pharmacy.
About $245 and a $50 copay for Medicare
The Medicare piece is the bigger policy shift. For Medicare enrollees, the out-of-pocket cost runs about $245, with a $50 monthly copay, available as of April 1, 2026. What makes that significant is the coverage itself: Medicare has historically not paid for drugs used purely for weight loss, so extending coverage to these obesity treatments marks a real change in what the program will pay for. For an older adult managing weight-related health conditions, that shift can turn a medication that was simply unavailable through their coverage into one they can access with a modest copay. Enrollees should still expect the usual rules around prescriptions and plan coverage to apply, and coverage can vary by plan, so the $50 copay figure describes the arrangement rather than guaranteeing every enrollee’s exact cost. How Medicare drug costs generally work is explained on the government’s Medicare costs page.
Cheaper pills may be next
The pricing arrangement also looks ahead to a new format. Future oral GLP-1 pills, which are pending FDA approval, are slated to be priced at about $149 a month. A pill version matters because it would drop the price further and remove the injections that some patients find off-putting, potentially widening who is willing to start. Those pills are not on the market yet, though, and their availability depends on the regulatory review clearing, so the $149 figure describes an intended price for a product that still needs approval rather than something a patient can buy today.
Eligibility and prescriber rules still apply
None of these prices bypass the medical gatekeeping around these drugs. A prescription is still required, and eligibility and prescriber requirements continue to apply, meaning a clinician has to determine the medication is appropriate before anyone gets it at any price. That matters because these are powerful medications with real side effects, and the lower price does not change the need for a doctor’s involvement or ongoing monitoring. A patient cannot simply order the drug at the discounted rate without meeting whatever clinical criteria the program and prescriber set. The lower numbers change the affordability calculation for a lot of households and, for Medicare enrollees, open a door that was previously closed, but the drugs remain prescription treatments, not something available on demand. Anyone weighing the cost should confirm the current price for their specific dose and their specific coverage, since the deal’s figures are phasing in on a schedule that runs through 2026 and beyond.
This article was produced with AI assistance and reviewed by a human editor. Figures are linked to their primary sources; where a claim could not be verified from the public record, we say so.
More Financial Reading
